Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life

Frontiers in Cardiovascular Medicine

article

Paolo Madeddu¹  Elisa Avolio¹  Valeria Vincenza Alvino¹  Marianna Santopaolo¹  Gaia Spinetti² 

[1] Translational Health Sciences, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol;Laboratory of Cardiovascular Research

关键词: aging;    regenerative;    cardiovascular;    stratification;    personalized medicine;    congenital heart disease;    bone marrow;    frailty;   

DOI  :  10.3389/fcvm.2019.00177

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Cardiovascular regenerative medicine is an exciting new approach that promises to change the current care of million people world-wide. Major emphasis was given to the quality and quantities of regenerative products, but recent evidence points to the importance of a better specification of the target population that may take advantage of these advanced medical treatments. Patient stratification is an important step in drug development. Tailoring treatment to the patient's specificity allowed significant improvement in cancer therapy, but personalized regenerative medicine is still at the initial stage in the cardiovascular field. For example, new-borns with a congenital heart condition and elderly people require dedicated therapeutic approaches, which adapt to their lifetime needs. In these people, personalized treatments may overcome the benefits delivered by standard protocols. In this review, we provide insights into these extreme stages of life as potential targets for cardiovascular reconstitution.

【 授权许可】

CC BY